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Abstract  
 
Background: Symptoms of anxiety and depression in patients with restless legs syndrome (RLS) have 
been observed. However, it is unclear whether rates of threshold depression and anxiety disorders 
according to DSM-IV criteria in such patients are also elevated.   
Methods: 238 RLS patients were assessed with a standardized diagnostic interview (Munich- 
Composite International Diagnostic Interview for DSM-IV) validated for subjects aged 18–65 years. 
Rates of anxiety and depressive disorders were compared between 130 RLS patients within this age 
range and 2265 community respondents from a nationally representative sample with somatic 
morbidity of other types.    
Results: RLS patients revealed an increased risk of having 12-month anxiety and depressive disorders 
with particularly strong associations with panic disorder (OR=4.7; 95% CI=2.1–10.1), generalized 
anxiety disorder (OR=3.5; 95% CI= 1.7–7.1), and major depression (OR=2.6; 95% CI=1.5–4.4). In 
addition, lifetime rates of panic disorder and most depressive disorders as well as comorbid depression 
and anxiety disorders were considerably increased among RLS patients compared with controls.    
Conclusions: The results suggest that RLS patients are at increased risk of having specific anxiety and 
depressive disorders. Causal attributions of patients suggest that a considerable proportion of the 
excess morbidity for depression and panic disorder might be due to RLS symptomatology.   
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Introduction 
 
In the 19th century Wittmaack first described the co-occurrence of restless legs syndrome 
(RLS) with symptoms of depression and anxiety and suggested the term “anxietas tibiarum” 
for the condition [29]. He further proposed the classification of this syndrome as a form of 
“neurasthenia” [13]. Early investigators noted that RLS occurs particularly in “anxious, tense, 
or depressed patients” [6]. Using questionnaires, recent studies have shown up increased 
symptoms of anxiety and depression among RLS patients [1, 9, 10, 17]. However, up to now 
no data have been available to investigate whether RLS patients are at increased risk for 
specific psychiatric disorders, especially those from the anxiety and depression spectrum.   
The present study examined rates of depression and anxiety disorders according to DSM-IV 
diagnostic criteria [20] in patients with RLS, and compares these rates with controls from a 
community sample with a somatic illness. 
 
 
Methods 
 
Consecutive inpatients and outpatients of the Movement Disorder Unit at the Max Planck 
Institute of Psychiatry,Munich diagnosed with idiopathic RLS [23] were included in the 
study.The patients were contacted by letter describing the aim and design of the study. After 
written informed consent was obtained patients were scheduled for a telephone interview. The 
subjects were studied within a previously reported investigation addressing the mode of 
inheritance of RLS [25].Assessments were based on a computer-assisted personal interview 
using the Munich-Composite International Diagnostic Interview for DSM-IV (DIA-X/M-
CIDI), a modified version of the World Health Organisation CIDI, version 1.2., supplemented 
by questions to cover DSM-IV and ICD-10 criteria [28]. The M-CIDI allows for the 
assessment of symptoms, syndromes and diagnoses according to DSMIV criteria of specific 
mental disorders along with information about onset, duration, and clinical and psychosocial 
severity. Test-retest reliability and validity for the full M-CIDI have been reported elsewhere 
[16, 27]. The performance of the interview took 30 minutes and was completed in a single 
contact. For the purpose of this report, CIDIDSM- IV algorithms [15] for the diagnosis of 
depression (major depressive episode DSM-IV: 296.2 and dysthymia DSM-IV: 300.4) as well 
as anxiety disorders (panic disorder DSM-IV 300.21 and generalized anxiety disorder (GAD): 
DSM-IV 300.02) are considered. It was also investigated within the CIDI assessment whether 
the depressive or anxiety disorder – according to the patient’s attribution – was almost 
(exclusively) due to a significant somatic condition as summarized in the DSM-IV exclusion 
criteria [20] (depression due to a general medical condition DSM-IV: 293.83 and anxiety 
disorder due to a general medical condition DSM-IV: 293.89). In addition, the sole 
occurrence of panic attacks not meeting the full diagnostic criteria for a panic disorder was 
considered. All diagnoses were assessed for the past 12-month time frames along with 
information about the age of first onset. Apart from GAD, the lifetime history of the 
respective condition was also assessed. Any differences between pharmacologically treated 
and untreated RLS patients were also investigated.   
All interviews were performed by two highly trained DIA-X/MCIDI interviewers with 
clinical backgrounds who had received special training (MP and BS). Interviewers were 
closely monitored throughout the entire study period.   
The control group consisted of subjects selected out of 4181 subjects in the German National 
Health Interview and Examinations Survey – Mental Health Supplement (GNH – MHS) [8], a 
community survey of the German general population examined using the same method as the 
RLS group for mental and somatic morbidity. To control for non-specific effects of somatic 
illness on the rates of mental disorder, only subjects with one or more somatic diagnoses were 
included. However, control subjects with any neurological or nephrological disorder were 
excluded in the comparative analysis because of the known occurrence of secondary RLS [2, 
24] (n=2265).   
Analyses were performed using Stat 7 [22] and applying the information sandwich estimator 
for accurate assessment of precision of estimated measures in the case of weighted data [18]. 
For binary outcomes, associations were quantified with the odds ratios (OR) from logistic 
regression [11] while adjusting for age and gender. In addition, the interaction restless 
legs*sex and restless less*age for all mental disorders as outcome were tested. In the case of a 
significant interaction we included the respective interaction term(s) and calculated then the 
odds ratio adjusted to the mean age and female rate in the general population, that is: 
ORadj=exp [b(main effect restless legs)+b(restless legs*female 
gender)*0.4767105+b(age)*42.32755)] with b(.)=ln(OR(.)).   
Every control subject had been given a weighting factor by a quantum- weighting program to 
account for differential sampling probabilities and to match the distribution of the sampling 
frame.   
 
 
Results 
 
Because the assessment instrument, the M-CIDI for DSM-IV (DIA-X/M-CIDI) [28] is 
specifically validated for subjects aged 18–65 years, only patients within this age range 
(n=130) were included in the final analysis. For the reader’s information, prevalence rates of 
depression and anxiety disorders of RLS patients aged 65 or above (n=108) are also presented 
in the tables. No control group, however, is available for this age range.   
The mean age of the patients (n=130, 71 female and 59 males) was 55.3 years (SD=8.2).Of 
4181 GNH – MHS controls, 2265 subjects had a somatic but no neurological or nephrological 
disorder. The mean age of these subjects (1166 female and 1099 male) was 42.3 years 
(SD=13.1).   
Compared with the controls, RLS patients reported higher 12-month rates of any depressive 
disorder (OR=2.6,95% confidence interval (CI)=1.5–4.4),panic attacks (OR=2.9, 95% 
CI=1.4–5.4; OR adjusted for mean control group=5.4; 95% CI=2.5–11.7),panic disorder 
(OR=5.2, 95% CI=2.4–11.3; OR adjusted for mean control group=10.1; 95% CI=4.5–22.4), 
or generalized anxiety disorder (OR=3.7, 95% CI=1.8–7.4). When examining comorbidity 
rates, RLS subjects were also more likely to present with comorbid anxiety-depression 
(OR=2.1, 95% CI=1.0–4.0); the association between depressive and panic disorder (OR=3.6, 
95% CI=1.0–11.8) is particularly noteworthy. Table 1 gives 12-month prevalence rates of any 
depressive and anxiety disorders as well as selected diagnostic subgroups. Rates for panic 
attack in both groups and the odds ratio RLS vs. controls are also shown.   
Closer inspection further revealed that in comparison with controls with at least one other 
physical disorder, RLS patients more frequently attributed major depressive episodes to a 
general medical condition (8.5% vs. 1%, OR=13.2, 95% CI=5.4–32.2) as proposed in DSM-
IV. Compared with controls, RLS patients with depression attributed, in particular, their sleep 
disturbances (47.8 % vs. 5.4%, OR=12.7, 95% CI=4.0–40.7), depressed mood (43.5% vs. 
3.1%, OR=24.9, 95% CI=7.5–82.3), reduced interest (34.8% vs. 2.8%, OR=19.7, 95% 
CI=5.2–74.2) and suicidal thoughts (34.8 % vs. 2.6%,OR=24.1, 95% CI=6.4–90.5) as being 
entirely and always due to their RLS symptoms. Lifetime rates were higher and associations 
of RLS and depression and panic disorder were comparable (see Table 2). Again, a higher rate 
of RLS patients attributing their major depressive episodes to a general medical condition 
(1385% vs. 1.8%, OR=8.45, 95% CI=4.1–17.1) was found.   
The analysis of age-of-onset characteristics of specific depressive disorders and panic disorder 
among RLS patients revealed that in most of the patients the psychiatric disorder appeared 
after the onset of RLS. This is the case in 76.7% of patients with major depression, 83.3% of 
patients with dysthymia, 63.6% of patients with GAD, and 60% of patients with panic 
disorder, all of whom describe the occurrence of RLS before the onset of the psychiatric 
disorders.   
Eighty-two percent of RLS patients received pharmacological treatment of their RLS, most 
often with dopaminergic medication. Comparing the prevalence rates of depression and 
anxiety disorders of patients with (n=107) and without (n=23) pharmacological treatment of 
their RLS no significant group differences emerged. The 12-month prevalence rates for MDE 
were 8.7 % vs. 9.4% (OR=1.49; 95% CI=0.27–8.34), for dysthymia 8.7 vs. 4.7 (OR 0.47, 
95% CI 0.08–2.65), for GAD 4.4 vs. 9.4 (OR=2.21, 95 % CI 0.27–18.32), and for panic 
disorder 8.7 vs. 8.4 (OR 1.35,95 % CI 0.23–7.94). The lifetime prevalence rates for MDE 
were 8.7% vs. 26.2% (OR=4.04; 95% CI=0.87–18.74), for dysthymia 8.7 vs. 4.7 (OR 0.47, 95 
% CI 0.08–2.65), for GAD 4.4 vs. 9.4 (OR=2.21, 95 % CI 0.27–18.32), and for panic disorder 
8.7 vs. 12.2 (OR 1.91, 95 % CI 0.35–10.46).   
 
 
Discussion 
 
The main finding of our study is that RLS patients are at increased risk for DSM-IV 
depressive and anxiety disorders. The temporal relationship between depression, panic 
disorder and RLS suggests that in most cases RLS occurs as the primary condition. This 
pattern of tempo tion that their mental disorder symptoms might be caused by their RLS 
symptoms.   
Because it is well known that somatic disorders e. g. diabetes [3],cardiovascular disorders 
[12] or cancer [21] increase the risk of depression and some anxiety disorders [30], we 
allowed for this association in our analyses by comparing RLS patients with a subset of age-
adjusted community respondents suffering from at least one somatic disorder. It should be 
noted that this control strategy is a strong test and although the control group was not 
specifically scrutinized for possible RLS symptoms the exclusion of control subjects with 
diseases known to be associated with the RLS obviously minimizes RLS-cases within the 
controls. Considering the older age of the RLS-patients and the sex difference in comparison 
to the controls we have statistically corrected for age and gender. Our finding, even in this 
strict comparison, that RLS patients have significantly higher rates of both depressive and 
anxiety disorders (particularly from the GAD and panic spectrum) is remarkable. It suggests 
that RLS patients are at an even higher risk of psychiatric disorder than patients with other 
somatic disorders. Although the patients’ causal attribution suggests that some of this excess 
mental disorder morbidity might be explained by the direct or indirect effect of RLS, 
suggesting some pathophysiologic pathway, it is noteworthy that this relationship does not 
sufficiently explain the observed association. Furthermore, this association is also of strong 
clinical relevance because it is known that antidepressants can aggravate RLS [7, 14]. The 
importance of the need for specific treatment of the mental illness in RLS patients is also 
supported by the high number of the patients (38%) reporting suicidal thoughts due to their 
RLS symptoms. Taken together our results call for further studies on the role and efficacy of 
antidepressants in RLS-patients, particularly because some patients also experienced an 
improvement in their RLS symptoms with antidepressant treatment [5].   
Possible mechanisms by which RLS increases the risk of specific depressive and anxiety 
disorders are not known at the moment. It could be that sleep disturbances may increase the 
risk of these disorders and it is well known that sleep disturbances can increase the risk of 
depressive disorders [4]. Furthermore, sleep deprivation can worsen panic disorder [19] and 
may, in susceptible subjects, trigger a panic disorder. However, currently used medication for 
the treatment of RLS such as dopaminergic, GABAA-ergic and opioidergic compounds may 
also influence the development of depression and anxiety disorders in susceptible RLS 
patients. Our own exploratory analysis could not detect any differences between treated and 
untreated RLS patients. However, as only 23 RLS patients did not receive pharmacological 
treatment, and the number of patients with specific depressive or anxiety disorders did not 
exceed three, this exploratory analysis lacks the power to detect subtle effects.   
Because RLS is a highly familial disorder [26], the increased risk of specific depressive and 
anxiety disorders could have a genetic etiology as well, and it needs to be investigated 
whether both the neurological and psychiatric conditions segregate within the same families.   
Although the clinical association of RLS and depression and anxiety disorders had already 
been described in the 19th century, our study confirms this clinical observation using 
standardized diagnostic criteria for the first time. It should now be possible to explore the 
mechanisms involved in this specific comorbidity and to evaluate the implications for the 
treatment of these common neurological and psychiatric disorders. Our findings underline the 
need for further studies on the role and efficacy of antidepressants in RLS.      
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